title: Burnout: evaluation of the efficacy and tolerability of TARGET 1® for professional fatigue syndrome (burnout).
abstract: OBJECTIVE
  To study the effect of a dietary supplement (TARGET 1®: a combination of casozepine, taurine, Eleutherococcus senticosus and extramel) on burnout symptomatology.
  
  
  METHODS
  A 12-week, double-blind, randomized, placebo-controlled trial was conducted in workers engaged in professional contact with patients, students or clients. All were affected by burnout syndrome based on a score of ≥4 on the Burnout Measure Scale (BMS-10). The primary outcome measure was the change in the BMS-10 score; secondary outcome measures included the change in the Maslach's Burnout Inventory scale-Human Service Survey (MBI-HSS) score and the Beck Depression Inventory. Five scores were evaluated.
  
  
  RESULTS
  Eighty-seven participants were enrolled in the study: 44 received the active formulation (verum group); 43 received placebo. After 12 weeks' supplementation, the placebo group showed significant improvements in scores for BMS-10, MBI-HSS fatigue and the Beck Depression Inventory, but MBI-HSS depersonalization and task management were not improved; the verum group showed significant improvements in all five scores. The verum group consistently showed significantly greater improvements in scores than the placebo group.
  
  
  CONCLUSIONS
  TARGET 1® significantly improved the symptoms of burnout after 12 weeks' use.
authors.affiliation: Department of Clinical Pharmacology, University of Bordeaux Ségalen, Bordeaux, France docteur.alain.jacquet@wanadoo.fr.
authors.forename: Alain
authors.initials: A
authors.lastname: Jacquet
authors.affiliation: Department of Clinical Pharmacology, University of Bordeaux Ségalen, Bordeaux, France INSERM CIC-P0005, Bordeaux, France.
authors.forename: Adeline
authors.initials: A
authors.lastname: Grolleau
authors.affiliation: INSERM CIC-P0005, Bordeaux, France ADERA, Pessac, France.
authors.forename: Jérémy
authors.initials: J
authors.lastname: Jove
authors.affiliation: INSERM CIC-P0005, Bordeaux, France ADERA, Pessac, France.
authors.forename: Régis
authors.initials: R
authors.lastname: Lassalle
authors.affiliation: Department of Clinical Pharmacology, University of Bordeaux Ségalen, Bordeaux, France INSERM CIC-P0005, Bordeaux, France INSERM U657, Bordeaux, France.
authors.forename: Nicholas
authors.initials: N
authors.lastname: Moore
mesh_terms: D000328:Adult; D002055:Burnout, Professional / Q000188:drug therapy*; D002211:Capsaicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019587:Dietary Supplements; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D010919:Placebos; D010936:Plant Extracts / Q000009:adverse effects* / Q000627:therapeutic use*; D013482:Superoxide Dismutase / Q000009:adverse effects* / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D013654:Taurine / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome; D064232:Visual Analog Scale
chemical_list: D004338:Drug Combinations; D010919:Placebos; D010936:Plant Extracts; C000602145:TARGET 1 dietary supplement; D013654:Taurine; D013482:Superoxide Dismutase; D002211:Capsaicin
keywords: Burnout; TARGET 1®; dietary supplement; professional fatigue